Research programme: astrocyte-derived neurotrophic factors - Amarantus BioScience

Drug Profile

Research programme: astrocyte-derived neurotrophic factors - Amarantus BioScience

Alternative Names: AMRS-001; CDNF - Amarantus Bioscience; Conserved dopaminergic neurotrophic factor; MANF; MANF-based therapeutics - Amarantus BioScience; Mesencephalic astrocyte-derived neurotrophic factor

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Amarantus Therapeutics; University of Miami
  • Developer Amarantus Bioscience Holdings; Generex Biotechnology Corporation
  • Class Nerve growth factors; Recombinant proteins
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Retinal vein occlusion
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma; Macular degeneration; Parkinson's disease; Retinal vein occlusion; Retinitis pigmentosa; Spinocerebellar degeneration; Stroke
  • Research Alzheimer's disease
  • No development reported Amyotrophic lateral sclerosis; Brain injuries; Diabetes mellitus; Ischaemic heart disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top